These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 32812511)
1. Protective effects of deferoxamine on lead-induced cardiotoxicity in rats. Gazeri A; Aminzadeh A Toxicol Ind Health; 2020 Oct; 36(10):800-806. PubMed ID: 32812511 [TBL] [Abstract][Full Text] [Related]
2. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Saad SY; Najjar TA; Al-Rikabi AC Pharmacol Res; 2001 Mar; 43(3):211-8. PubMed ID: 11401411 [TBL] [Abstract][Full Text] [Related]
3. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats. Emara AM; El Kelany RS; Moustafa KA Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166 [TBL] [Abstract][Full Text] [Related]
5. Activation of the molecular and functional effects of Nrf2 against chronic iron oxide nanorod overload-induced cardiotoxicity. Elgharabawy RM; Elgharbawy DM; Emara AM Hum Exp Toxicol; 2018 Aug; 37(8):870-885. PubMed ID: 29172713 [TBL] [Abstract][Full Text] [Related]
6. Iron-chelating agents attenuate NMDA-Induced neuronal injury via reduction of oxidative stress in the rat retina. Sakamoto K; Suzuki T; Takahashi K; Koguchi T; Hirayama T; Mori A; Nakahara T; Nagasawa H; Ishii K Exp Eye Res; 2018 Jun; 171():30-36. PubMed ID: 29530811 [TBL] [Abstract][Full Text] [Related]
7. Deferoxamine alleviates liver fibrosis induced by CCl4 in rats. Mohammed A; Abd Al Haleem EN; El-Bakly WM; El-Demerdash E Clin Exp Pharmacol Physiol; 2016 Aug; 43(8):760-8. PubMed ID: 27168353 [TBL] [Abstract][Full Text] [Related]
8. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity. Umemura M; Kim JH; Aoyama H; Hoshino Y; Fukumura H; Nakakaji R; Sato I; Ohtake M; Akimoto T; Narikawa M; Tanaka R; Fujita T; Yokoyama U; Taguri M; Okumura S; Sato M; Eguchi H; Ishikawa Y J Pharmacol Sci; 2017 Aug; 134(4):203-210. PubMed ID: 28779994 [TBL] [Abstract][Full Text] [Related]
9. Protection against acetaminophen-induced liver injury in vivo by an iron chelator, deferoxamine. Sakaida I; Kayano K; Wasaki S; Nagatomi A; Matsumura Y; Okita K Scand J Gastroenterol; 1995 Jan; 30(1):61-7. PubMed ID: 7701253 [TBL] [Abstract][Full Text] [Related]
10. Deferoxamine-induced neurite outgrowth and synapse formation in postnatal rat dorsal root ganglion (DRG) cell cultures. Nowicki M; Kosacka J; Spanel-Borowski K; Borlak J Eur J Cell Biol; 2009 Oct; 88(10):551-62. PubMed ID: 19581022 [TBL] [Abstract][Full Text] [Related]
11. Attenuation of bleomycin-induced lung injury and oxidative stress by N-acetylcysteine plus deferoxamine. Teixeira KC; Soares FS; Rocha LG; Silveira PC; Silva LA; Valença SS; Dal Pizzol F; Streck EL; Pinho RA Pulm Pharmacol Ther; 2008; 21(2):309-16. PubMed ID: 17904883 [TBL] [Abstract][Full Text] [Related]
12. Iron-induced oxidative rat liver injury after non-heart-beating warm ischemia is mediated by tumor necrosis factor α and prevented by deferoxamine. Niu X; Huang WH; De Boer B; Delriviere L; Mou LJ; Jeffrey GP Liver Transpl; 2014 Aug; 20(8):904-11. PubMed ID: 24753220 [TBL] [Abstract][Full Text] [Related]
13. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418 [TBL] [Abstract][Full Text] [Related]
14. The long-acting parenteral iron chelator, hydroxyethyl starch-deferoxamine, fails to protect against alcohol-induced liver injury in rats. Sadrzadeh SM; Hallaway PE; Nanji AA J Pharmacol Exp Ther; 1997 Feb; 280(2):1038-42. PubMed ID: 9023321 [TBL] [Abstract][Full Text] [Related]
15. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Tajima S; Ikeda Y; Sawada K; Yamano N; Horinouchi Y; Kihira Y; Ishizawa K; Izawa-Ishizawa Y; Kawazoe K; Tomita S; Minakuchi K; Tsuchiya K; Tamaki T Am J Physiol Endocrinol Metab; 2012 Jan; 302(1):E77-86. PubMed ID: 21917632 [TBL] [Abstract][Full Text] [Related]
16. Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation. Fine JM; Renner DB; Forsberg AC; Cameron RA; Galick BT; Le C; Conway PM; Stroebel BM; Frey WH; Hanson LR Neurosci Lett; 2015 Jan; 584():362-7. PubMed ID: 25445365 [TBL] [Abstract][Full Text] [Related]
17. Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. Zeinivand M; Nahavandi A; Zare M Inflammopharmacology; 2020 Apr; 28(2):575-583. PubMed ID: 31786804 [TBL] [Abstract][Full Text] [Related]
18. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380 [TBL] [Abstract][Full Text] [Related]
19. Comparison of deferoxamine and methylprednisolone: protective effect of pharmacological agents on lipid peroxidation in spinal cord injury in rats. Dinc C; Iplikcioglu AC; Atabey C; Eroglu A; Topuz K; Ipcioglu O; Demirel D Spine (Phila Pa 1976); 2013 Dec; 38(26):E1649-55. PubMed ID: 24108296 [TBL] [Abstract][Full Text] [Related]